Literature DB >> 6907016

Affinity-chromatographic purification of human alpha 2-antiplasmin.

B Wiman.   

Abstract

A new simple and efficient purification method for alpha 2-antiplasmin is described that is based on the interaction between alpha 2-antiplasmin and a fragment from elastase-digested plasminogen constituting the three N-terminal triple-loop structures in the plasmin A-chain (LBSI). After a single-step adsorption of the alpha 2-antiplasmin from plasminogen-depleted plasma to LBSI-Sepharose and elution with 6-aminohexanoic acid, an 80-90% pure preparation with a yield of 50-60% is obtained. The major impurity is fibrinogen, which can easily be removed by gel filtration, and, as a result, a homogeneous fully active alpha 2-antiplasmin preparation is obtained that has the same properties as previously described for alpha 2-antiplasmin. Evidence is put forward that a form of alpha 2-antiplasmin with less affinity for the lysine-binding sites in plasminogen may exist, even in unfractionated plasma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6907016      PMCID: PMC1162201          DOI: 10.1042/bj1910229

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  16 in total

Review 1.  Fast-acting plasmin inhibitor in human plasma.

Authors:  D Collen; B Wiman
Journal:  Blood       Date:  1978-04       Impact factor: 22.113

2.  The primary inhibitor of plasmin in human plasma.

Authors:  S Müllertz; I Clemmensen
Journal:  Biochem J       Date:  1976-12-01       Impact factor: 3.857

3.  Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma.

Authors:  B Wiman; D Collen
Journal:  Eur J Biochem       Date:  1977-08-15

4.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

5.  Quantitative immunoelectrophoresis of human serum proteins.

Authors:  H G Clarke; T Freeman
Journal:  Clin Sci       Date:  1968-10       Impact factor: 6.124

6.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

7.  Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides.

Authors:  R Axén; J Porath; S Ernback
Journal:  Nature       Date:  1967-06-24       Impact factor: 49.962

8.  Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound.

Authors:  B Wiman; P Wallén
Journal:  Eur J Biochem       Date:  1973-07-02

9.  Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.

Authors:  D Collen
Journal:  Eur J Biochem       Date:  1976-10-01

10.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

View more
  20 in total

1.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

2.  Kinetics of the reaction of streptokinase-plasmin complex with purified human and mouse alpha 2-macroglobulin. Implications for mechanism.

Authors:  P K Anonick; W H Vetter; S L Gonias
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

3.  Alpha 2-macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse. Comparison with alpha 2-antiplasmin in simultaneous reaction experiments.

Authors:  S L Gonias; N L Figler
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

4.  Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma.

Authors:  K Bangert; A H Johnsen; U Christensen; S Thorsen
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

5.  Complex formation of platelet thrombospondin with fibrinogen.

Authors:  L L Leung; R L Nachman
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

6.  An examination of the inhibitory mechanism of serpins by analysing the interaction of trypsin and chymotrypsin with alpha 2-antiplasmin.

Authors:  J J Enghild; Z Valnickova; I B Thøgersen; S V Pizzo; G Salvesen
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

7.  The AH-site of plasminogen and two C-terminal fragments. A weak lysine-binding site preferring ligands not carrying a free carboxylate function.

Authors:  U Christensen
Journal:  Biochem J       Date:  1984-10-15       Impact factor: 3.857

8.  Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.

Authors:  Christophe Dommke; Oliver Turschner; Jean-Marie Stassen; Frans Van de Werf; H Roger Lijnen; Peter Verhamme
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

9.  Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

Authors:  R I Levin; P C Harpel; D Weil; T S Chang; D B Rifkin
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

10.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.